Gapping up
In reaction to earnings/guidance:
- VRT +25.1%, POWL +24.9%, CDLX +18.5%, ELF +16.9%, ROVR +16.1%, FRSH +15.1%, YOU +12.2%, MTCH +10.7%, COCO +9.4%, TEVA +6.8%, UTHR +6.7%, MDXG +6.4%, OLO +6.4%, AZPN +5.3% (also terminates Micromine purchase; also authorizes new $300 mln share repurchase program), FDP +5%, AVDX +4.9%, TEX +4.8%, EMR +4.8%, ICPT +4.8%, BGNE +4.7%, BLDR +4.7%, FLS +4.5%, EHC +4.3%, SWTX +3.9%, SSRM +3.7%, SPNS +3.7%, HUM +3.3%, OMCL +3.1%, DFIN +3%, HAYW +3%, ANDE +2.9%, INSP +2.7%, VMEO +2.7%, XYL +2.7%, VREX +2.6%, AMD +2.6%, ROCK +2.6%, APAM +2.4%, PSN +2.3%, AIZ +2.2%, UIS +2.1%, HPP +2%, AVA +2%, TPB +2%, CVS +1.9%, MTRN +1.9%, CHEF +1.7%, BG +1.6%, PERI +1.6%, FIS +1.6%, ROAD +1.6%, ULCC +1.5%, ABC +1.5%, WAT +1.5%, MATX +1.4%, ADC +1.4%, VAL +1.4%, PXD +1.3% (also declares base-plus-variable cash dividend of $1.84/sh), ENLC +1.3%, AHT +1.3%, VOYA +1.2% (also doubles dividend; also authorizes share repurchase of additional $500 mln), VRSK +1.2%, SHOO +1.1%
Other news:
- PAG +5.8% (to join S&P MidCap 400)
- ERIE +5% (to join S&P MidCap 400)
- IDYA +2% (IDEAYA and Amgen (AMGN) Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) Tumors)
- HII +1.8% (awarded US Navy contract)
- AGI +1% (reports new results from its ongoing exploration program)
Analyst comments:
- OSK +0.6% (upgraded to Outperform from Neutral at Robert Baird)